Anti-inflammatory activity of salmeterol: down-regulation of cytokine production
| Autor: | L. Sekut, K. M. Connolly, K. Page, B. R. Champion, J. A. Menius |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1995 |
| Předmět: |
Lipopolysaccharides
medicine.medical_specialty medicine.medical_treatment T cell T-Lymphocytes Immunology Galactosamine Pharmacology Lymphocyte Activation chemistry.chemical_compound Mice In vivo Internal medicine medicine Immunology and Allergy Animals Albuterol Salmeterol Xinafoate Mice Inbred C3H business.industry Tumor Necrosis Factor-alpha Adrenergic beta-Agonists Shock Septic respiratory tract diseases Mice Inbred C57BL Endocrinology Cytokine medicine.anatomical_structure chemistry Mechanism of action Cytokines Cytokine secretion Tumor necrosis factor alpha Female Salmeterol medicine.symptom business medicine.drug Research Article |
| Popis: | SUMMARY Elevation of intracellular cAMP levels has been shown previously to inhibit cytokine secretion by various cell types in vitro. Since salmeterol is a β2-agonist which activates adenylate cyclase, its ability to inhibit cytokine production was evaluated. Though salmeterol, and the related drug albuterol, did not inhibit IL-1β production in vitro, both drugs did inhibit tumour necrosis factor-alpha (TNF-α) secretion by lipopolysaccharide (LPS)-activated THP-1 cells with similar IC50S of approximately 0·1μm. This inhibition was effectively reversed by the β2-antagonist oxprenolol, indicating that the inhibition was mediated through the β2-adrenergic receptor. A strikingly different reactivity profile was seen with T cells. Salmeterol was able to inhibit the activation of both mouse and human T cells, as measured by proliferation and IL-2 secretion in response to anti-CD3 antibody, whereas albuterol was completely inactive in these assays. This T cell inhibition by salmeterol was about 10-fold less potent than that for TNF-α production, and was not reversed by a β2-antagonist, indicating that a different mechanism was involved in the effect of salmeterol on T cells. Paralleling the TNF-a inhibitory activity in vitro, oral dosing of salmeterol and albuterol inhibited LPS-induced increase in murine serum TNF level in vivo, with ED50s of approximately 0·1 mg/kg. This inhibition could be abrogated by dosing orally with the β-blocker propranolol. The long-acting pharmacological profile of salmeterol was apparent in that it maintained its efficacy for 3h, while albuterol had a much shorter duration of action. Salmeterol also had some protective effects in the galactosamine/LPS model of endotoxic shock, which is dependent upon TNF-α production. Though salmeterol inhibited serum TNF-α levels by up to 94% in this assay, it protected less than 50% of the animals from the lethal effects of the LPS/galactosamine mixture. This observation suggests that functional levels of TNF-α localized in tissues may not be accurately reflected by serum levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|